Trends and Outcomes of Transcatheter Aortic Valve Implantation (TAVI) and Surgical Aortic Valve Replacement (SAVR) in Cancer and Noncancer Patients: A Nationwide Analysis
Authors' conclusion
TAVI in patients with prostate, breast, lung, and renal cancer appears to be a reasonable alternative to SAVR with lower or similar risks of mortality and MACE.
Study context
- Population
- Patients with severe AS and active or prior prostate, lung, colorectal, breast or renal cancer (and noncancer patients)matched: 345,413 noncancer, 33,565 cancer
- Participants
- 1,505,995 patients
- Exposure
- TAVI vs SAVR
- Outcome
- MACE and its components
Methodological detailspropensity-score matched, Nationwide Inpatient Sample database (2002-2018)
- Propensity-score matched
- Nationwide Inpatient Sample database (2002-2018)
Main finding
As reported in the abstract
MACE, by cancer type
TAVI vs SAVRAdjusted odds ratio (95% CI)
Lung cancer
0.65(0.43–0.97)
Prostate cancer
0.79(0.66–0.96)
Colorectal cancer
1.43(1.08–1.90)
Observational data: associations, not effects.
Further findings
In-hospital mortality, by cancer type
- Lower with TAVI in prostate cancer; no difference among other cancer types
TAVI utilisation trend
- Steep yearly increase in TAVI use
Safety
Major bleeding
- Lower with TAVI (except lung cancer)
Stroke
- Similar between TAVI and SAVR (except colorectal cancer)
Original publication
Trends and Outcomes of TAVI and SAVR in Cancer and Noncancer Patients: A Nationwide Analysis. JACC Adv. Published 27 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →